Who are PRC-063's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Solriamfetol Oral Tablet [Sunosi].

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/prc-063.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

PRC-063 — Competitive Intelligence Brief

PRC-063 (PRC-063) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Stimulant; dopamine and norepinephrine reuptake inhibitor. Area: Psychiatry / Neurology.

phase 3 Stimulant; dopamine and norepinephrine reuptake inhibitor Dopamine transporter (DAT); norepinephrine transporter (NET) Psychiatry / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

PRC-063 (PRC-063) — Rhodes Pharmaceuticals, L.P.. PRC-063 is an extended-release formulation of methylphenidate that provides sustained dopamine and norepinephrine reuptake inhibition for ADHD symptom management.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
PRC-063 TARGET	PRC-063	Rhodes Pharmaceuticals, L.P.	phase 3	Stimulant; dopamine and norepinephrine reuptake inhibitor	Dopamine transporter (DAT); norepinephrine transporter (NET)
Solriamfetol Oral Tablet [Sunosi]	Solriamfetol Oral Tablet [Sunosi]	Rochester Center for Behavioral Medicine	marketed	Dopamine and norepinephrine reuptake inhibitor	Dopamine transporter (DAT) and norepinephrine transporter (NET)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Stimulant; dopamine and norepinephrine reuptake inhibitor class)

Rhodes Pharmaceuticals, L.P. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PRC-063 — Competitive Intelligence Brief. https://druglandscape.com/ci/prc-063. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab